Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
For those early stage resectable NSCLC patients who received neoadjuvant chemoimmunotherapy as per Checkmate816 and did not attain a pCR, what are the adjuvant immunotherapy treatment strategies if EGFR negative?
Related Questions
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
Is there a role for surgical debulking for patients with stage IV lung sarcomatoid carcinoma?
Would you consider using trastuzumab deruxtecan in HER2-low expressing NSCLC based on data from breast cancer?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
What are your top takeaways in Thoracic Cancers from ASCO 2023?
Do you think it's appropriate to run separate NGS panels on biopsies from lesions in both the right and left lung in a patient suspected of two lung primaries?
Is there a role for pemetrexed in the treatment of metastatic adenosquamous NSCLC?
What are strategies to deal with grade 3/4 anorexia associated with Osimertinib?
Would you consider ALK-directed TKI for a ALK L1198F point mutation in a patient with metastatic lung adenocarcinoma after progressing through first line chemoimmunotherapy?